Newsroom

Sorted by: Latest

-

Omdia:顶级云厂商加码AI基础设施,2025年第四季度,全球云基础设施支出增长29%

伦敦--(BUSINESS WIRE)--(美国商业资讯)-- Omdia数据显示,2025年第四季度,全球云基础设施服务支出达到1109亿美元,同比增长29%。增速较上一季度进一步加快,这已是市场连续第六个季度实现超过20%的增长。随着企业对AI的需求从实验阶段转向生产部署阶段,顶级云厂商(hyperscalers)正持续加大投资,以扩展AI基础设施容量。展望2026年,Omdia预测全球云基础设施服务支出将增长27%。未来市场竞争的差异化将越来越取决于基础设施规模、资本效率以及AI智能体(AI agent)相关平台能力的完善程度上。 在本季度,亚马逊云科技(AWS) 的增长加速至24%,而微软Azure 和谷歌云分别实现39%和 50%的同比增长。AI 需求已不再局限于 GPU 等专用算力,同时也在推动CPU、存储和网络等更广泛的基础设施需求增长。企业正加速围绕agent、工作流和数据整合构建 AI 应用,对具备编排、扩展与治理能力的一体化云环境的需求持续增长。这进一步强化了云平台作为 AI 基础的核心地位,同时也推动更多传统及新兴工作负载向云端迁移。 与此同时,AWS、微软Azu...
-

GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported estimated full-year consolidated financial results for 2025,1 as reviewed by the Audit Committee and the Board of Directors on March 25, 2026. The Board of Directors will approve the final accounts on A...
-

GenSight Biologics publie ses résultats financiers consolidés estimés pour l’année 2025

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN: FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour les maladies neurodégénératives de la rétine et du système nerveux central, publie aujourd’hui ses résultats financiers consolidés estimés pour l’année 2025, tels qu'ils ont été examinés par le Comité d'Audit et par le Conseil d'Administration en date du 25 mars 2026...
-

3D Investment Partners Discloses materials that organize in detail the process by which the Toho HD Audit and Supervisory Committee reached its decision not to start litigation, and that point out the unreasonableness of the decision-making process

TOKYO--(BUSINESS WIRE)--A fund which is provided discretionary investment management services by 3D Investment Partners Pte. Ltd. (together with such fund, “3D” or “we”) demanded, in December 2025, Toho Holdings Co., Ltd. (TOKYO: 8129, "Toho HD") file a lawsuit with respect to alleged breaches of the duty of care of the directors arising from past bid‑rigging misconduct involving current and former directors of Toho HD. In response, the Audit and Supervisory Committee of Toho HD decided not to...
-

Polish Investment and Trade Agency (PAIH) Names Ascend Elements’ Project Apex 2 Manufacturing Investment of the Year

WARSAW, Poland--(BUSINESS WIRE)--The Polish Investment and Trade Agency (PAIH) has named Ascend Elements’ Project Apex 2 its Manufacturing Investment of the Year, focused on the company’s development of the EU’s first fully integrated battery materials refining center that will turn spent lithium‑ion batteries into new, low‑carbon cathode materials using its Hydro‑to‑Cathode® technology. The Republic of Poland has granted Ascend Elements USD 320 million (approximately 1.22 billion PLN) to advan...
-

ABIONYX Pharma Achieves Major Milestone in apoA-I Biomanufacturing with Breakthrough in Synthetic Sphingomyelin Production

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – eligible for PEA PME), a next-generation biopharmaceutical company developing innovative therapies in sepsis and critical care based on an exclusive apoA-I technology platform, today announced a significant technological and industrial breakthrough combining high-performance apoA-I bioproduction with exclusive mastery of ultra-pure synthetic sphingomyelin, paving the way for a new clas...
-

ABIONYX Pharma réalise une avancée majeure dans la production de son biomédicament CER-001 en réalisant une percée unique au monde dans la production de sphingomyéline synthétique

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – éligible PEA PME), société biopharmaceutique de nouvelle génération qui développe des thérapies innovantes dans le sepsis et les soins intensifs, fondées sur une plateforme technologique exclusive basée sur l’apoA- I, annonce aujourd’hui une avancée décisive combinant bioproduction haute performance de l’apolipoprotéine A-I (apoA-I) et maîtrise exclusive d’une sphingomyéline synthétiqu...
-

Nidec Announces the Future Nomination of Director Candidates for New Nidec

KYOTO, Japan--(BUSINESS WIRE)--Nidec Corporation (the “Company”), as part of its efforts to strengthen corporate governance based on the report of the Third-Party Committee published on March 3 as well as the Improvement Plan and the Status Report published by the Company on January 28, is revising the composition of its Board of Directors so that the Board can perform its functions effectively by including directors who possess diverse knowledge, experience, and expertise. In advance of the 53...
-

Entertainment Industry Veterans Launch Unified Production Platform (UPP)

LOS ANGELES--(BUSINESS WIRE)--Unified Production Platform (UPP) today announced its official launch, led by founder Mujeebur Rahmansaher and partners Greg Smith and An De Vooght—three entertainment industry veterans who collectively built, scaled, and successfully exited one of the industry’s most prominent production companies. UPP is a SaaS-based, cloud-native, AI-powered production management platform that unifies casting, payroll, compliance, analytics, and workflow management into a single...
-

NTT Solmare and Good Smile Company Announce Strategic Partnership for New Visual Novel "Obey Me! Sinner's Choice"; Wishlist Now on Steam

OSAKA, Japan--(BUSINESS WIRE)--NTT Solmare Corporation and Good Smile Company, Inc. have announced the joint production of a new visual novel game, "Obey Me! Sinner's Choice" ....